TY - JOUR
T1 - A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of CaV1.3 L-Type Calcium Channels
AU - Cooper, Garry
AU - Kang, Soosung
AU - Perez-Rosello, Tamara
AU - Guzman, Jaime N.
AU - Galtieri, Daniel
AU - Xie, Zhong
AU - Kondapalli, Jyothisri
AU - Mordell, Jack
AU - Silverman, Richard B.
AU - Surmeier, D. James
N1 - Publisher Copyright:
© 2020 American Chemical Society.
PY - 2020/9/18
Y1 - 2020/9/18
N2 - Ca2+ channels with a CaV1.3 pore-forming α1 subunit have been implicated in both neurodegenerative and neuropsychiatric disorders, motivating the development of selective and potent inhibitors of CaV1.3 versus CaV1.2 channels, the calcium channels implicated in hypertensive disorders. We have previously identified pyrimidine-2,4,6-triones (PYTs) that preferentially inhibit CaV1.3 channels, but the structural determinants of their interaction with the channel have not been identified, impeding their development into drugs. By a combination of biochemical, computational, and molecular biological approaches, it was found that PYTs bind to the dihydropyridine (DHP) binding pocket of the CaV1.3 subunit, establishing them as negative allosteric modulators of channel gating. Site-directed mutagenesis, based on homology models of CaV1.3 and CaV1.2 channels, revealed that a single amino acid residue within the DHP binding pocket (M1078) is responsible for the selectivity of PYTs for CaV1.3 over CaV1.2. In addition to providing direction for chemical optimization, these results suggest that, like dihydropyridines, PYTs have pharmacological features that could make them of broad clinical utility.
AB - Ca2+ channels with a CaV1.3 pore-forming α1 subunit have been implicated in both neurodegenerative and neuropsychiatric disorders, motivating the development of selective and potent inhibitors of CaV1.3 versus CaV1.2 channels, the calcium channels implicated in hypertensive disorders. We have previously identified pyrimidine-2,4,6-triones (PYTs) that preferentially inhibit CaV1.3 channels, but the structural determinants of their interaction with the channel have not been identified, impeding their development into drugs. By a combination of biochemical, computational, and molecular biological approaches, it was found that PYTs bind to the dihydropyridine (DHP) binding pocket of the CaV1.3 subunit, establishing them as negative allosteric modulators of channel gating. Site-directed mutagenesis, based on homology models of CaV1.3 and CaV1.2 channels, revealed that a single amino acid residue within the DHP binding pocket (M1078) is responsible for the selectivity of PYTs for CaV1.3 over CaV1.2. In addition to providing direction for chemical optimization, these results suggest that, like dihydropyridines, PYTs have pharmacological features that could make them of broad clinical utility.
UR - http://www.scopus.com/inward/record.url?scp=85091264219&partnerID=8YFLogxK
U2 - 10.1021/acschembio.0c00577
DO - 10.1021/acschembio.0c00577
M3 - Article
C2 - 32881483
AN - SCOPUS:85091264219
SN - 1554-8929
VL - 15
SP - 2539
EP - 2550
JO - ACS Chemical Biology
JF - ACS Chemical Biology
IS - 9
ER -